Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2019 , Vol 23 , Issue 6
Genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population
1Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Mersin University, Mersin, Turkey2Department of Biochemistry, Faculty of Pharmacy, Mersin University, Mersin, Turkey
3Mersin City Training and Research Hospital, Emergency Service, Mersin, Turkey DOI : 10.35333/jrp.2019.80 Many xenobiotic and endogenous compounds are transported from blood into hepatocytes mediated by organic anion transporter protein (OATP1B1), which is encoded by solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene. Genetic polymorphisms in SLCO1B1 gene can affect in pharmacokinetics of most compounds and may cause changes in drug efficacy and advers reactions. Thus, genetic polymorphism analysis of genes that may affect the pharmacokinetics of compounds is extremely important. The goal of this study was to determine the genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population and also to compare our results with the findings of other previously reported populations. Genotyping analyses of SLCO1B1 g.89595 T>C polymorphism was carried out in 68 healthy Turkish volunteers by a polymerase chain reaction-restriction fragment length polymorphism method. The frequencies of the TT, TC, and CC genotypes were 77.9, 19.1 and 3.0, respectively. Also, the frequencies of T and C alleles were 87.5 and 12.5, respectively. The genotype frequencies were consistent with Hardy–Weinberg equilibrium. The results of the study are compared with those of other ethnic groups, and they displayed pronounced ethnic group differences, especially East Asian and Southeast ancestry. The detection of SLCO1B1 polymorphisms may ensure benefits for adjustment of dosage regimens of some drugs and protecting from and/or decreasing adverse events, and also for future studies concerning SLCO1B1 transporter and its polymorphisms. Keywords : SLCO1B1; drug transporter; genetic polymorphism; Turkish population